Шварц Г.Я. Витамин D и D-гормон. М.: Анахарсис, 2005. 152 с.
Castro L.C. The vitamin D endocrine system. Arq Bras Endocrinol Metabol 2011;55(8):566–75.
Holick M.F. Vitamin D: the underappreciated D-lightful hormone that is important for skeletal and cellular health. Curr Opin Endocrinol Diabetes 2002;9:87–98.
Institute of Medicine, Food and Nutrition Board. Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC: Nat Acad Press, 2010.
Lee D.M., Tajar A., Pye S.R. et al.; EMAS study group. Association of hypogonadism with vitamin D status: the European Male Ageing Study. Eur J Endocrinol 2012;166(1): 77–85.
Nimptsch K., Platz E.A., Willett W.C., Giovannucci E. Association between plasma 25-OH vitamin D and testosterone levels in men. Clin Endocrinol 2012;77(1):106–12.
Pilz S., Frisch S., Koertke H. et al. Effect of vitamin D supplementation on testosterone levels in men. Horm Metab Res 2011;43(32): 223–5.
Wehr E., Pilz S., Boehm B.O. et al. Low free testosterone is associated with heart failure mortality in older men referred for coronary angiography. Eur J Heart Fail 2011;13(5):482–8.
Rojansky N., Brzezinski A., Schenker J.G. Seasonality in human reproduction: an update. Hum Reprod 1992;7(6):735–45.
Holick M.F., Binkley N.C., Bischoff-Ferrari H.A. et al.; Endocrine Society. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Мetab 2011;96(7):1911–30.
Wehr E., Pilz S., Boehm B.O. et al. Sex steroids and mortality in men referred for coronary angiography. Clin Endocrinol 2010;73(5):613–21.
Lerchbaum E., Pilz S., Boehm B.O. et al. Combination of low free testosterone and low vitamin D predicts mortality in older men referred for coronary angiography. Clin Endocrinol (Oxf) 2012;77(3):475–83.
Mordan-McCombs S., Brown T., Wang W.L. et al. Tumor progression in the LPB-Tag transgenic model of prostate cancer is altered by vitamin D receptor and serum testosterone status. J Steroid Biochem Mol Biol 2010;121(1–2):368–71.
Blomberg Jensen M. Vitamin D metabolism, sex hormones, and male reproductive function. Reproduction 2012;144(2):135–52.
Glass A.R., Swerdloff R.S., Bray G.A. et al. Low serum testosterone and sex-hormonebinding-globulin in massively obese men. J Clin Endocrinol Metab 1977;45(6):1211–9.
Jorde R., Grimnes G., Hutchinson M.S. et al. Supplementation with vitamin D does not increase serum testosterone levels in healthy males. Horm Metab Res 2013;45(9): 675–81.
Bellastella G., Maiorino M.I., Olita L. et al. Vitamin D deficiency in type 2 diabetic patients with hypogonadism. J Sex Med 2014; 11(2):536–42.
Wehr E., Pilz S., Schweighofer N. et al. Association of hypovitaminosis D with metabolic disturbances in polycystic ovary syndrome. Eur J Endocrinol 2009;161(4): 575–82.
Talaei A., Mohamadi M., Adgi Z. The effect of vitamin D on insulin resistance in patients with type 2 diabetes. Diabetol Metab Syndr 2013;5(1):8.
Kim T.N., Park M.S., Lim K.I. et al. Relationships between sarcopenic obesity and insulin resistance, inflammation, and vitamin D status: the Korean Sarcopenic Obesity Study. Clin Endocrinol (Oxf) 2013;78 (4): 525–32.
Hurskainen A.R., Virtanen J.K., Tuomainen T.P. et al. Association of serum 25-hydroxyvitamin D with type 2 diabetes and markers of insulin resistance in a general older population in Finland. Diabetes Metab Res Rev 2012;28(5):418–23.
Wortsman J., Matsuoka L.Y., Chen T.C. et al. Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr 2000;72(3):690–3.
Compston J.E., Vedi S., Ledger J.E. et al. Vitamin D status and bone histomorphometry in gross obesity. Am J Clin Nutr 1981;34(11): 2359–63.
Kamycheva E., Joakimsen R.M., Jorde R. Intakes of calcium and vitamin D predict body mass index in the population of Northern Norway. J Nutr 2003;133(1):102–6.
Li H.W., Brereton R.E., Anderson R.A. et al. Vitamin D deficiency is common and associated with metabolic risk factors in patients with polycystic ovary syndrome. Metabolism 2011;60(10):1475–81.
Pittas A.G., Lau J., Hu F.B., Dawson-Hughes B. The role of vitamin D and calcium in type 2 diabetes. A systematic review and metaanalysis. J Clin Endocrinol Metab 2007;92(6):2017–29.
Maestro B., Dávila N., Carranza M.C., Calle C. Identification of a vitamin D response element in the human insulin receptor gene promoter. J Steroid Biochem Mol Biol 2003; 84(2–3):223–30.
Maestro B., Molero S., Bajo S. et al. Transcriptional activation of the human insulin receptor gene by 1,25-dihydroxyvitamin D(3). Cell Biochem Function 2002;20(3):227–32.
Milner R.D., Hales C.N. The role of calcium and magnesium in insulin secretion from rabbit pancreas studied in vitro. Diabetol 1967;3(1):47–9.
Bikle D. Nonclassic actions of vitamin D. J Clin Endocrinol Metab 2009;94(1):26–34.
Shoelson S.E., Herrero L., Naaz A. Obesity, inflammation, and insulin resistance. Gastroenterol 2007;132(6):2169–80.
Тюзиков И.А. Новые патогенетические подходы к диагностике заболеваний предстательной железы у мужчин с ожирением, андрогенным дефицитом и диабетической нейропатией. Андрол генит хир 2011;(4):34–9.
Тюзиков И.А. Синдром хронической тазовой/простатической боли и метаболический синдром у мужчин: патофизиологические корреляции и перспективы патогенетической полимодальной терапии. Медицинский алфавит. Больница 2014;(1):26–31.
Тюзиков И.А. Инсулинорезистентность как системный фактор патогенеза заболеваний почек (обзор литературы). Сахарный диабет 2014;(1):47–56.
Тюзиков И.А., Калинченко С.Ю., Ворслов Л.О. Тишова Ю.А. Бессимптомная доброкачественная гиперплазия предстательной железы: три стороны одной проблемы. Рус мед журн 2013;34:1768–73.
Тюзиков И.А. Метаболический синдром и мужское бесплодие (обзор литературы). Андрол генит хир 2013;(2):5–10.
Foresta C., Strapazzon G., De Toni L. et al. Bone mineral density and testicular failure: evidence for a role of vitamin D 25-hydroxylase in human testis. J Clin Endocrinol Metab 2011;96(4):646–52.
Shinkyo R., Sakaki T., Kamakura M. et al. Metabolism of vitamin D by human microsomal CYP2R1. Biochem Biophys Res Commun 2004;324(1):451–7.
Pitman M.S., Cheetham P.J., Hruby G.W., Katz A.E. Vitamin D deficiency in the urological population: a single center analysis. J Urol 2011;186(4):1395–9.
Тюзиков И.А. Гормон D-статус у мужчин с андрологической патологией (пилотное исследование). Материалы X конгресса «Мужское здоровье» с международным участием. Минск, 2014. С. 89–91.
Тишова Ю.А., Ворслов Л.О., Жуков А.Ю. и др. Распространенность дефицита D-гормона (25ОНD3) у пациентов с ожирением в России: ретроспективное популяционное исследование. Материалы VII Международного конгресса ISSAM. М., 2013. С. 78–9.
Adorini L., Penna G. Control of autoimmune diseases by the vitamin D endocrine system. Nat Clin Pract Rheumatol 2008;4(8):404–12.
Motrich R.D., van Etten E., Depovere J. et al. Impact of vitamin D receptor activity on experimental autoimmune prostatitis. J Autoimmun 2009;32(2):140–8.
Crescioli C., Villari D., Forti G. et al. Des (1-3) IGF-I-stimulated growth of human stromal BPH cells is inhibited by a vitamin D3 analogue. Mol Cell Endocrinol 2002;198(1–2): 69–75.
Penna G., Amuchastegui S., Cossetti C. et al. Treatment of experimental autoimmune prostatitis in nonobese diabetic mice by the vitamin D receptor agonist elocalcitol. J Immunol 2006;177(12):8504–11.
Ghosn J., Viard J.P. Vitamin D and infectious diseases. Presse Med 2013;42(10):1371–6.
Hewison M. Antibacterial effects of vitamin D. Nat Rev Endocrinol 2011;7(6):337–45.
Manchanda P.K., Kibler A.J., Zhang M. et al. Vitamin D receptor as a therapeutic target for benign prostatic hyperplasia. Indian J Urol 2012;28(4):377–81.
Sampson N., Madersbacher S., Berger P. Pathophysiology and therapy of benign prostatic hyperplasia. Wien Klin Wochenschr 2008;120(13–14):390–401.
Habuchi T., Suzuki T., Sasaki R. et al. Association of vitamin D receptor gene polymorphism with prostate cancer and benign prostatic hyperplasia in a Japanese population. Cancer Res 2000;60(2):305–8.
Espinosa G., Esposito R., Kazzazi A., Djavan B. Vitamin D and benign prostatic hyperplasia – a review. Can J Urol 2013;20(4): 6820–5.
Ruan L., Zhong W.D., Li Z.M., Hua X. Relationship between vitamin D receptor gene Fok I polymorphisms and benign prostatic hyperplasia complicated by histological prostatitis. Zhonghua Nan Ke Xue 2011; 17(10):880–3.
Kivineva M., Bläuer M., Syvälä H. et al. Localization of 1,25-dihydroxyvitamin D3 receptor (VDR) expression in human prostate. J Steroid Biochem Mol Biol 1998;66(3): 121–7.
Haghsheno M.A., Mellström D., Behre C.J. et al. Low 25-OH vitamin D is associated with benign prostatic hyperplasia. J Urol 2013; 190(2):608–14.
Comeglio P., Chavalmane A.K., Fibbi B. et al. Human prostatic urethra expresses vitamin D receptor and responds to vitamin D receptor ligation. J Endocrinol Invest 2010; 33(10):730–8.
Adorini L., Penna G., Fibbi B., Maggi M. Vitamin D receptor agonists target static, dynamic, and inflammatory components of benign prostatic hyperplasia. Ann NY Acad Sci 2010;1193:146–52.
Mullan R.J., Bergstralh E.J., Farmer S.A. et al. Growth factor, cytokine, and vitamin D receptor polymorphisms and risk of benign prostatic hyperplasia in a community-based cohort of men. Urolоgy 2006;67(2): 300–5.
Crescioli C., Morelli A., Adorini L. et al. Human bladder as a novel target for vitamin D receptor ligands. J Clin Endocrinol Metab 2005;90(2):962–72.
Gandini S., Boniol M., Haukka J. et al. Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma. Int J Cancer 2011;128(6): 1414–24.
Xu Y., Shao X., Yao Y. et al. Positive association between circulating 25-hydroxyvitamin D levels and prostate cancer risk: new findings from an updated meta-analysis. J Cancer Res Clin Oncol 2014;140 (9):1465–77.
Meyer H.E., Robsahm T.E., Bjørge T. et al. Vitamin D, season, and risk of prostate cancer: a nested case-control study within Norwegian health studies. Am J Clin Nutr 2013;97(1): 147–54.
Xu Y., He B., Pan Y. et al. Systematic review and meta-analysis on vitamin D receptor polymorphisms and cancer risk. Tumour Biol 2014;35(5):4153–69.
Fortmann S.P., Burda B.U., Senger C.A. et al. Vitamin, Mineral, and Multivitamin Supplements for the Primary Prevention of Cardiovascular Disease and Cancer. A Systematic Evidence Review for the U.S. Preventive Services Task Force. Rockville (MD): Agency for Healthcare Research and Quality (US); 2013.
Chung M., Lee J., Terasawa T. et al. Vitamin D with or without calcium supplementation for prevention of cancer and fractures: an updated meta-analysis for the U.S. Preventive Services Task Force. Ann Intern Med 2011;155(12):827–38.
Grant W.B. Vitamin D status: ready for guiding prostate cancer diagnosis and treatment? Clin Cancer Res 2014;20(9): 2241–3.
Тюзиков И.А., Калинченко С.Ю., Ворслов Л.О. и др. Витамин D, мужское здоровье и мужская репродукция. Андрол генит хир 2013;(4):36–44.
Gorbachinsky I., Akpinar H., Assimos D.G. Metabolic syndrome and urological diseases. Rev Urol 2010;12(4): 157–80.
Gsur A., Madersbacher S., Haidinger G. et al. Vitamin D receptor gene polymorphism and prostate cancer risk. Prostate 2002;51(1): 30–4.